Strategic Collaborations Context has multiple TCE bispecific assets (CTIM-76, CT-95, CT-202) and an exclusive BA3362 license, creating clear out-licensing or co-development opportunities for pharma partners seeking solid-tumor expansions. Use AACR data and upcoming posters as outreach proof points, with targeted pitches around Claudin-6, Mesothelin, and Nectin-4 programs.

Combination Opportunities Opportunity to explore combination therapies with checkpoint inhibitors or other immunotherapies to enhance efficacy and market potential. Propose PD-1/PD-L1 or CTLA-4 co-development discussions across select CT assets, with translational data to de-risk trials.

Early Stage Support Lean team dynamics suggest potential for strategic support in early-stage development, regulatory planning, and translational research. Propose scope-limited collaborations to accelerate IND enabling and first-in-human studies, plus biomarker strategies.

Data Outreach Active conference presence and data generation hint at readiness for data-driven partnerships. Propose data-sharing agreements, sponsored trials, and co-funding options around AACR presentations to attract partners.

Manufacturing Partnerships Manufacturing and supply chain readiness is critical for bispecifics. Offer manufacturing development and scale-up partnerships with CDMOs/CMOs to de-risk late-stage production, including process development and GMP supply for CT assets.